Story
Haleon Boosts US Sales by Targeting Side Effects of GLP-1 Weight-Loss Drugs
Summary
The consumer health giant is partnering with retailers like CVS to create dedicated in-store displays for products like TUMS and Advil, resulting in a significant sales lift from the growing number of GLP-1 users.
Consumer health company Haleon is successfully increasing U.S. sales by marketing its over-the-counter products to the rapidly growing number of consumers using GLP-1 weight-loss drugs. The company is strategically placing products that alleviate common side effects in dedicated retail displays, capitalizing on the pharmaceutical megatrend.
A New In-Store Strategy
Haleon, the maker of Advil, TUMS, and Biotène, is working with retailers including CVS Pharmacy to create curated shelf space for users of GLP-1 medications like Wegovy and Zepbound. These drugs are known to have side effects such as nausea, constipation, and abdominal pain, which Haleon's products can help manage.
A company spokesperson stated that this "dual placement" strategy—featuring products in both their regular aisles and in new "GLP-1 destination sets"—delivered an average 24% sales lift per store during the first quarter. The spokesperson added that "Haleon holds the majority of GLP-1 shelf space at CVS."
Tapping a Growing Market
AdThe move targets a significant and expanding demographic. According to analytics firm Gallup, approximately 11% of Americans are currently taking GLP-1 drugs for weight loss. By addressing the common side effects of these popular medications, Haleon is positioning its existing portfolio to serve a new and specific consumer need.
CVS Pharmacy confirmed it is adapting to this trend, stating it has "expanded its product assortment and is highlighting CVS brand and national brand over-the-counter products to help make managing side effects easier." The retailer did not comment directly on its arrangement with Haleon.
Broader Retail Push
The strategy appears to be part of a broader push by the London-listed company. The Haleon spokesperson confirmed it has also held discussions with retail giants Walmart and Target about its GLP-1 in-store strategy, though the outcome of those talks was not disclosed. This initiative demonstrates how consumer health companies are adapting to capture ancillary revenue from major shifts in the pharmaceutical landscape.
Read next
More on Stocks
Nucor Stock Slides After Q3 Earnings Guidance Misses Analyst Forecasts
Nucor Corporation (NUE) shares fell after the company projected third-quarter earnings of $5.55 to $5.65 per share, below the Wall Street consensus of $5.99, citing the absence of significant one-time gains from the prior quarter.
Disney Asks Court to Halt FCC License Review, Alleges Political Pressure From Trump
The Walt Disney Company has filed a legal challenge to stop the Federal Communications Commission from conducting an early review of its ABC station licenses, claiming the regulator is acting on President Trump's directives.
Starbucks Settles Florida Lawsuit Over Diversity Policies for $1 Million
The coffee giant has agreed to settle a lawsuit with Florida's attorney general, pledging to avoid race- or sex-based quotas in its employment practices and pay $1 million to cover the state's litigation costs.
Latin American Stocks Rally as Dollar Slides After Fed Rate Hike
Equities and currencies across Latin America gained as a pullback in the U.S. dollar following the Federal Reserve's latest interest rate increase boosted commodity-linked assets and improved investor sentiment toward emerging markets.